The RRRR study is the first randomized trial to compare the efficacy of the treatment strategy between the investigational treatment in which the dose of infliximab was decided based on the baseline serum TNF, and the standard dose (3 mg/kg) of infliximab in established patients with RA exhibiting an inadequate response to MTX. Here, TNF is linked to rheumatoid arthritis.